Invega Sustenna

Invega Sustenna

paliperidone

Manufacturer:

Janssen

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Paliperidone palmitate
Indications/Uses
Acute & maintenance treatment of schizophrenia in adults. Schizoaffective disorder in adults as monotherapy & adjunct to mood stabilizers or antidepressants.
Dosage/Direction for Use
Schizophrenia Initially 150 mg on day 1 & 100 mg 1 wk later by deep IM inj, followed by mthly maintenance dose: 75 mg. Dose may be adjusted w/in range: 25-150 mg. Schizoaffective disorder Initially 150 mg on day 1 & 100 mg 1 wk later by deep IM inj. Mthly maintenance dose range: 50-150 mg. Mild renal impairment (CrCl ≥50 to <80 mL/min) Initially 100 mg on day 1 & 75 mg 1 wk later by deep IM inj, followed by mthly dose: 50 mg. Dose may be adjusted w/in range: 25-100 mg.
Contraindications
Hypersensitivity to paliperidone or risperidone.
Special Precautions
Discontinue use if hypersensitivity reactions, neuroleptic malignant syndrome or tardive dyskinesia/extrapyramidal symptoms occur. Not to be inj in divided doses, intravascularly or SC. Avoid inadvertent inj into blood vessel. History of cardiac arrhythmias, congenital long QT syndrome; hyperglycemia & DM; wt gain; known CV or cerebrovascular disease or conditions predisposing to hypotension; seizures or conditions lowering seizure threshold; clinically significant low WBC or drug-induced leukopenia/neutropenia; risk factors for venous thromboembolism; Parkinson's disease & dementia w/ Lewy bodies; priapism. Intraoperative floppy iris syndrome. Antiemetic effect. Conditions contributing to core body temp elevation or dehydration. Concomitant use w/ risperidone; psychostimulants eg, mehthylphenidate; drugs known to prolong QT interval. May affect ability to drive & use machines. Not recommended in moderate or severe renal impairment. Hepatic impairment. Pregnancy. Not to be used during lactation. Ped <18 yr. Elderly w/ dementia.
Adverse Reactions
Drug Interactions
Antagonized effect of l-dopa & other dopamine agonists. Decreased mean steady-state Cmax & AUC w/ carbamazepine. Increased Cmax & AUC w/ divalproex Na. Emergence of extrapyramidal symptoms w/ psychostimulants eg, methylphenidate. Drugs known to prolong QT interval; centrally-acting drugs, alcohol.
MIMS Class
ATC Classification
N05AX13 - paliperidone ; Belongs to the class of other antipsychotics.
Presentation/Packing
Form
Invega Sustenna inj 25 mg
Packing/Price
1's
Form
Invega Sustenna inj 100 mg
Packing/Price
1's
Form
Invega Sustenna inj 150 mg
Packing/Price
1's
Form
Invega Sustenna inj 75 mg
Packing/Price
1's
Form
Invega Sustenna inj 50 mg
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in